CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Mirabegron 50 MG +1 moredrug
Likely dose
Mirabegron 50 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06133075
NCT06133075Phase 2Completed
CompareCT.gov

Using Mirabegron to Increase Blood Pressure in Patients With Postural Orthostatic Tachycardia Syndrome

Cedars-Sinai Medical Center·interventional·Posted Nov 15, 2023·Updated Apr 8, 2026

In Brief

A Phase 2 clinical trial evaluating Mirabegron 50 MG and Mirabegron 25 MG for Postural Orthostatic Tachycardia Syndrome and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and overactive bladder (OAB) symptoms in patients with postural orthostatic tachycardia syndrome (POTS) who have a documented history of hypotension inadequately responsive to conventional treatments. The American Heart Association funds this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance, Syncope
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedNov 15, 2023
Enrollment StartDec 22, 2023
Primary CompletionMay 20, 2025
Study CompletionJul 25, 2025
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 2.6 years ago

Interventions

Mirabegron 50 MGdrug

10 patients will receive drug for 8 weeks

Mirabegron 25 MGdrug

10 patients will receive drug for 8 weeks